United Therapeutics: Familial Primary Pulmonary Hypertension trials

The registry lists 33 Familial Primary Pulmonary Hypertension studies with United Therapeutics as lead sponsor. 1 are open to participants now and 20 have results posted.

Phase 1 2Phase 2 8Phase 3 12Phase 4 8No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionEnrolling by invitationNCT03683186Phase 3
• Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using TyvasoCompletedNCT03950739Phase 1Results posted
• Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAHCompletedNCT03888365Results posted
• A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial HypertensionTerminatedNCT03657095Phase 3Results posted
• EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial HypertensionCompletedNCT03497689Phase 4Results posted
• TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)CompletedNCT03055221Phase 4Results posted
• Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)CompletedNCT02847260Phase 4Results posted
• Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial HypertensionCompletedNCT02279745Phase 2Results posted
• Safety and Efficacy of APD811 in Pulmonary Arterial HypertensionCompletedNCT02279160Phase 2Results posted
• Beraprost-314d Added-on to Tyvaso® (BEAT)CompletedNCT01908699Phase 3Results posted
• Remodulin® to Oral Treprostinil TransitionCompletedNCT01588405Phase 2Results posted
• An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionCompletedNCT01560637Phase 3Results posted
• Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral MonotherapyCompletedNCT01560624Phase 3Results posted
• Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®CompletedNCT01477333Phase 2Results posted
• Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH TherapiesCompletedNCT01266265Results posted
• An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial HypertensionCompletedNCT01027949Phase 3Results posted
• Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) PatientsCompletedNCT00990314Phase 2Results posted
• Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)CompletedNCT00989963Phase 2Results posted
• An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) PatientsCompletedNCT00792571Phase 2Results posted
• Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) SubjectsCompletedNCT00741819Phase 4Results posted
• Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAHTerminatedNCT00439946Phase 4Results posted
• Evaluate Real-World Use of Next Generation Infusion Pumps to Administer RemodulinTerminatedNCT05060315
• A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH PatientsCompletedNCT03626688Phase 3
• Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAHWithdrawnNCT03016468Phase 2
• Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial HypertensionWithdrawnNCT02999906Phase 3
• Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial HypertensionWithdrawnNCT02893995Phase 4
• An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial HypertensionWithdrawnNCT02882126Phase 4
• Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)TerminatedNCT01795950Phase 1
• Inhaled Treprostinil for PAH: Open-label ExtensionWithdrawnNCT01557660Phase 3
• Safety and Efficacy of Inhaled Treprostinil in Patients With PAHWithdrawnNCT01557647Phase 3
• A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 InhibitorWithdrawnNCT01458236Phase 3
• A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial HypertensionCompletedNCT00058929Phase 4
• Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary HypertensionCompletedNCT00004497Phase 3